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both at the transcriptional level and at the level of iNOS enzyme activity.
Whether a-pinene is selective for iNOS or also inhibits the other NOS
isoforms will have to be determined. The dual mode of action of a-pinene
may represent an advantage over other agents that either inhibit NF-úB
activation or iNOS activity, making it promising as an anti-osteoarthritic
drug.
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Purpose: This study investigated using injectable, drug-loaded micro-
spheres to prolong the delivery of small molecule drugs to the intraartic-
ular (IA) space of the knee joint while minimizing systemic exposure.
Biocompatibility was evaluated and in vitro drug release rates were
compared to in vivo release and bioactivity.
Methods: Microsphere characterization: Drugs were either obtained
commercially (naproxen and celecoxib) or prepared by known published
methods (cipemastat). Poly(D,L-lactide) (PLA) microspheres loaded with
either naproxen (NSAID), celecoxib (COX-2 inhibitor), or cipemastat
(MMP inhibitor) were prepared using an oil in oil emulsion method and
fractionated to a 38−75 mm size range. In vitro release was conducted
under physiologic conditions (PBS, 37ºC); drug release was quantiﬁed
by HPLC.
Biocompatibility: PLA microspheres suspended in hylan G-F 20 (5% w/v;
50ml) were injected into stiﬂe joints of normal guinea pigs. At 1 week
and 4 months after injection, gross morphometric analysis (joint width)
and histologic assessments of decalciﬁed cartilage, bone, and synovium
were performed to assess the acute and chronic biocompatibility of the
delivery system.
PK and bioactivity: Naproxen, celecoxib, and cipemastat loaded PLA
microspheres were administered to the knee joints of rabbits 4 weeks after
ACL transection. Plasma drug levels were monitored over 4 days after IA
injection to establish systemic PK proﬁles. At 4 days post-injection, drug
levels were assessed in local tissues. At 2 weeks post-injection, PGE-2
levels in synovial ﬂuid were measured to assess the relative bioactivities
of released celecoxib and naproxen.
Figure 1. PGE-2 levels in synovial ﬂuid.
Results: Microsphere charcterization: Naproxen, celecoxib and cipemas-
tat showed completed release from microspheres over 7, 30 and 45 days,
respectively giving associated half-lives of <1, 8, and 24 days.
Biocompatibility: Placebo microspheres showed median total synovial
and synovial inﬂammation scores equivalent to the control (hylan G-F 20).
Similarly, microspheres were not associated with any increased incidence
or severity of articular cartilage degeneration relative to the naive joints.
PK and bioactivity: Plasma PK proﬁles of drug released from micro-
spheres mimicked in vitro release proﬁles. At four days, drug levels in
joint tissues greatly exceeded plasma levels with naproxen, celecoxib, and
cipemastat showing 5.3, 38.2 and 22.4mg/mL in synovium, 1.7, 10.2 and
0.075mg/mL in synovial ﬂuid and 0.035, 0.009 and 0.007 mg/mL in plasma,
respectively. At day 14, PGE-2 levels were lower in celecoxib treated
OA joints than in either control or naproxen treated joints, suggesting
maintenance of COX-2 inhibitory activity, although this difference did not
reach statistical signiﬁcance.
Conclusions: PLA microspheres are well-tolerated in the IA space as
evidenced by histologic analysis of joint tissues. In addition, microspheres
targeted drugs to the IA space by providing therapeutic levels to local
tissues with minimal systemic exposure. As predicted by in vitro release
proﬁles, local, sustained delivery of celecoxib may have been effective at
suppressing PGE-2 levels in synovial ﬂuid over 14 days, while naproxen,
whose IA residence time was predicted to be no longer than 7 days, did
not have this effect.
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Purpose: In the course of prescribing chondroitin sulphate (CS) for the
treatment of knee osteoarthritis (KOA), it was observed that patients with
concomitant psoriasis (Ps) experienced a marked improvement of the
skin lesions. The aim of this pilot clinical trial was to assess the effects
of CS in patients with KOA and Ps.
Methods: 129 outpatients were enrolled in this multicentre, randomized,
double-blind, placebo (PBO) controlled clinical trial and received CS
800mg (Condrosan®, Bioibe´rica, Barcelona) once-a-day for a 3-month
treatment course. Patients were diagnosed with KOA according to
ACR criteria, radiological Kellgren-Lawrence score I-III, knee pain with
Huskisson’s VAS 30mm and plaque Ps with Psoriasis Area and
Severity Index (PASI) 5. The co-primary efﬁcacy outcomes were the
Huskisson’s VAS and the PASI. Joint and skin secondary parameters
included Lequesne’s algo-functional index, acetaminophen consumption,
Overall Lesion Severity Scale (OLS), Physician’s Global Assessment
(PGA) and evaluation of skin biopsies specimens. Quality-of-life was
determined with the SF-36 health survey and the Dermatology Life Quality
Index (DLQI). Global efﬁcacy and safety were evaluated by investigators
and patients with a semi-quantitative scale. These outcome measures
were assessed using ITT and PP and an ANCOVA was performed for all
statistical tests.
Results: At baseline, the study groups had moderate-severe KOA and
Ps and were balanced with respect to demographic and clinical variables.
CS was more effective than PBO in improving Huskisson’s VAS with
31.35±2.83mm in the CS group and 43.15±2.93mm for the PBO after
12 weeks of treatment (p< 0.01). The data regarding all the secondary
efﬁcacy parameters in rheumatology conﬁrmed the effect of CS with
statistical signiﬁcance at several end-points. There was a decrease in
acetaminophen consumption with 42.9% of patients using acetaminophen
in the CS group vs 64.0% in the PBO group at the end of the study
(p< 0.05). CS experienced a decrease of 4.57 points in the Lequesne’s
index vs 3.81 in the PBO group (p< 0.05).
After treatment with CS, patients experienced a mean decrease in PASI
score of 32.9%, without statistical signiﬁcance with respect to PBO.
However, the analysis of the different body areas affected with psoriatic
lesions determined with PGA showed that CS treatment improved plantar
Ps after 3 months treatment in 86.7% patients treated with CS vs 26.7%
in the PBO group (p< 0.05).
CS treatment improved quality of life in patients with both knee OA and
Ps, with statistical signiﬁcance vs PBO after 12 weeks treatment in some
subscales of both SF-36 and DLQI.
Tolerability was very good in both treatment groups. Adverse events
were infrequent and evenly distributed among groups. The PP analysis
conﬁrmed the results obtained by the ITT analysis.
Conclusions: The ﬁndings of this clinical trial conﬁrm the efﬁcacy and
safety of CS as a Symptomatic Slow-Acting Drug for Osteoarthritis
(SySADOA) reducing pain, improving physical function and quality of
life in patients with KOA. In view of the positive results with CS in the
treatment of plantar Ps, further studies should be performed to conﬁrm
the role of CS in this dermatologic disease. Moreover, the use of CS
could represent a special beneﬁt in patients with both pathologies since
NSAIDs have been reported to exacerbate preexisting Ps.
